Overview
Segolene Martin is the CEO and cofounder of Kantify, a company she cofounded in April 2016 and which is based in Brussels. She is also vice-chair of lifetech.brussels, where she has sat on the advisory board since February 2021, a working group member on innovation and commercialisation at the Global Partnership on Artificial Intelligence, and a member of the European Commission / Digital SME Focus Group on AI.
Her earlier roles include chief marketing officer at Meetsies, and two positions at CEN and CENELEC, where she was programme manager for innovation from 2011 to 2013 and then unit manager for technical policy until 2015. From December 2005 she was a policy officer responsible for research, innovation and business at the EU Representation Office of Regions Bretagne/Pays de la Loire/Poitou Charentes, and from 2009 she also coordinated the Automotive Crisis Intergroup at the Committee of the Regions. She worked at Euregio Maas Rijn in 2004 and at ERRIN in 2005.
She served on the boards of BeCode.org and Cluster software.brussels, and was Women in AI ambassador for Belgium from 2018 to 2022. She holds a master's degree in European public affairs from Sciences Po Strasbourg and an MBA from The Open University.
Career history
Media & appearances
- AI4Belgium & Data Science CommunityYouTubeDISUMMIT AI-Awards: Kantify announcement by Segolene MartinSegolene Martin announces that she is the CEO of Kantify, a machine learning consultancy, and that she has been nominated for an AI award. She invites viewers to vote for her and Kantify and mentions looking forward to meeting people at an event on June 26th.
- Leyton BeneluxYouTubeFull IV - Ségolène Martin (CEO Kantify)Ségolène Martin discusses how Kantify, her artificial intelligence-focused startup, uses AI technology to accelerate drug discovery for diseases like cancer and rare diseases that currently lack known treatments. She explains the company's three-pillar philosophy combining economic value with societal impact (providing hope to patients waiting for therapies) and environmental impact (testing far fewer molecules through AI screening rather than hundreds of thousands of chemical tests).
- Le VifYouTubeSégolène Martin - CEO de KantifySegolene Martin discusses her excitement about being a CEO in her thirties, noting that at this age she combines accumulated experience and professional networks with energy and time ahead of her. She identifies common traits among entrepreneurs and business creators as the desire to make a difference, ambition, and perseverance, and expresses her intention to continue working in technology and entrepreneurship for decades to come rather than retire.
In the news
- My sneakers and business cards are ready. I'll be looking forward to new and renewed interactions to share some of our latest progress on hard-to-drug targets. #NoHype
- Last sprint before BIO-Europe in Cologne. The theme of this year for Kantify: accelerating the discovery of molecules for Ion channels and GPCRs with AI. Get in touch with Segolene Martin if you have an undruggable target, regardless of the target family.
- This picture is so misleading that we even debated if I should post it here. Can you see the AlphaFold protein structure prediction behind me? Well, it is precisely to illustrate...that our AI platform Sapian isn't based on the notion of protein or molecular structures. So, don't be misled by this picture, we don't do structure-based drug discovery and that's one of the things that make our technology so orthogonal. This picture was taken during the Health track of the Flanders Technology & Innovation Festival. I explained the
- When small molecule discovery isn't structure-based, a new realm of possibilities opens. Layer by layer, discover some of the key features of our AI platform Sapian.
- Most virtual screening tools rely on static 3D protein structures, missing how proteins flex and shift in real biological environments. When targeting flexible pockets, allosteric sites, or proteins with no crystal structure, structure-based small molecule discovery quickly hits its limit. Our AI platform Sapian was trained on billions of molecular and proteomic data points to predict functional outcomes directly from 𝘴𝘦𝘲𝘶𝘦𝘯𝘤𝘦 𝘢𝘭𝘰𝘯𝘦. Without requiring structural prep or 3D snapshots, it enables target-agnostic,
- For those interested in target discovery and drug discovery in rare neuromuscular disorders using AI, Rubal will share some results.
- It feels pretty energizing to see such a concentration of Belgian health tech innovators on a single program. Look it up, and join us if you can. See by yourself how fruitful is the encounter between health and tech. Many thanks for inviting Kantify, Flanders Technology & Innovation Festival & Vlaamse overheid
- Rare neuromuscular disorders present unique diagnostic and therapeutic challenges. As part of the DREAMS Consortium, Kantify is working to bridge this gap using Artificial Intelligence. The webinar held by DREAMS on October 15th will answer to the question about how AI can help accelerate and improve our understanding and therapeutic quest for rare neuromuscular patients. Our speakers GoHun Seo, Rubal Ravinder, 💭 Christopher Rudolf will share actual results obtained with Artificial Intelligence in rare neuromuscular disorders,
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.